Das Cushing-Syndrom beim Hund – Klinik, Diagnose und
                    Therapie

Claudia E. Reusch

doi:10.1055/s-0032-1320155

kleintier konkret, Inhaltsverzeichnis

kleintier konkret 2012; 15(5): 22-35
DOI: 10.1055/s-0032-1320155

hund

endokrinologie

Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Das Cushing-Syndrom beim Hund – Klinik, Diagnose und Therapie

Claudia E. Reusch

Klinik für Kleintiermedizin, Vetsuisse-Fakultät, Universität Zürich

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Das Cushing-Syndrom stellt eine der häufigsten endokrinen Erkrankungen des Hundes dar. Es umfasst die Gesamtheit aller klinischen und biochemischen Veränderungen, die unter der Einwirkung einer chronisch erhöhten Glucocorticoidkonzentration entstehen. Zur Frage, wie die Erkrankung beim Hund korrekt zu benennen ist, gibt es momentan unterschiedliche Meinungen: Sie wird sowohl als Cushing-Syndrom als auch als Hyperadrenocortizismus oder als Hypercortisolismus bezeichnet. Im Rahmen des Artikels wird von Hypercortisolismus und Cushing-Syndrom gesprochen.

Volltext

Referenzen

Literatur
1 Alenza DP, Arenas C, Lopez ML et al. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 2006; 42(4): 269-276
2 Barker EN, Campbell S, Tebb AJ et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815
3 Behrend EN, Kemppainen RJ, Young DW. Effect of storage conditions on cortisol total thyroxine, and free thyroxine concentrations in serum and plasma of dogs. J Am Vet Med Assoc 1998; 212(19): 1564-1568
4 Benchekroun G, de Fornel-Thibaud P, Lafarge S et al. Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis. Vet Rec 2008; 163(6): 190-192
5 Benitah N, Feldman EC, Kass PH et al. Evaluation of serum 17-hydroxyprogesterone concentration after administration of ACTH in dogs with hyperadrenocorticism. J Am Vet Med Assoc 2005; 227: 1095-1101
6 Bertolini G, Furlanello T, Drigo M et al. Computed tomographic adrenal gland quantification in canine adrenocorticotroph hormone-dependent hyperadrenocorticism. Vet Radiol Ultrasound 2008; 49: 449-453
7 Bosje JT, Rijnberk A, Mol JA et al. Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism. Domest Anim Endocrinol 2002; 22: 201-210
8 Braddock JA, Church DB, Robertson ID et al. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 2003; 81(10): 600-607
9 Burkhardt WA, Guscetti F, Boretti FS et al. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats. Domest Anim Endocrinol 2011; 40(3): 155-164
10 Chapman PS, Mooney CT, Ede J et al. Evaluation of the basal and post-adrenocorticotrophic hormone serum concentrations of 17-hydroxyprogesterone for the diagnosis of hyperadrenocorticism in dogs. Vet Rec 2003; 153: 771-775
11 Chapman PS, Kelly DF, Archer J et al. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. J Small Anim Pract 2004; 45(6): 307-310
12 Eastwood JM, Elwood CM, Hurley KJ. Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract 2001; 44(3): 126-131
13 EQUAS XXXV, External Quality Assurance Program 2010. Michigan State University
14 Feldman EC, Nelson RW, Feldman MS. Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 1996; 209: 772-775
15 Feldman EC. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2011; 238(11): 1441-1451
16 Frank LA, DeNovo RC, Kraje AC et al. Cortisol concentrations following stimulation of healthy and adrenopathic dogs with two doses of tetracosactrin. J Small Anim Pract 2000; 41: 308-311
17 Frank LA, Schmeitzel LP, Oliver JW. Steroidogenic response of adrenal tissues after administration of ACTH to dogs with hypercortisolemia. J Am Vet Med Assoc 2001; 218(2): 214-216
18 Galac S, Kooistra HS, Teske E et al. Urinary corticoid/creatinine ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Vet Q 1997; 19(1): 17-20
19 Galac S, Kooistra HS, Voorhout G et al. Hyperadrenocorticism in a dog due to ectopic secretion of adrenocorticotropic hormone. Domest Anim Endocrinol 2005; 28(3): 338-348
20 Galac S, Kars VJ, Voorhout G et al. ACTH-independent hyperadrenocorticism due to food-dependent hypercortisolemia in a dog: a case report. Vet J 2008; 177(1): 141-143
21 Galac S, Buijtels JJ, Kooistra HS. Urinary corticoid: creatinine ratios in dogs with pituitary-dependent hypercortisolism during trilostane treatment. J Vet Intern Med 2009; 23(6): 1214-1219
22 Galac S, Reusch CE, Kooistra HS et al. Adrenals. In: Rijnberk A, Kooistra HS, (Hrsg) Clinical Endocrinology of Dogs and Cats. Hannover: Schlütersche Verlagsgesellschaft; 2010a 93-154
23 Galac S, Buijtels JJ, Mol JA et al. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism. Vet J 2010b 183(1): 75-80
24 Galeandro L, Sieber-Ruckstuhl N, Hartnack S et al. Evaluation of five immonoassays for measurement of urinary corticoid concentrations in dogs in comparison with gas chromatography-mass spectrometry results. ECVIM abstracts J Vet Intern Med 2010; 24(6): 1569
25 Hanson JM, van’t Hoofd MM, Voorhout G et al. Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 687-694
26 Helm JR, McLauchlan G, Boden LA et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med 2011; 25(2): 251-260
27 Hill KE, Scott-Moncrieff CR, Koshko MA et al. Secretion of sex hormones in dogs with adrenal dysfunction. J Am Vet Med Assoc 2005; 226: 556-561
28 Hoerauf A, Reusch C. Ultrasonographic characteristics of both adrenal glands in 15 dogs with functional adrenocortical tumors. J Am Anim Hosp Assoc 1999; 35(3): 193-199
29 Hurley K, Sturgess K, Cauvin A et al. The use of trilostane for the treatment of hyperadrenocorticism in dogs. J Vet Intern Med (abstract) 1998; 12: 210
30 Kerl ME, Peterson ME, Wallace MS et al. Evaluation of low-dose synthetic adrenocorticotropic hormone stimulation test in clinically normal dogs and dogs with naturally developing hyperadrenocorticism. J Am Vet Med Assoc 1999; 214(10): 1497-1501
31 Kooistra HS, Voorhout G, Mol JA et al. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1997; 152: 387-394
32 Martin LG, Behrend EN, Mealey KL et al. Effect of low doses of cosyntropin on serum cortisol concentrations in clinically normal dogs. Am J Vet Res 2007; 68(5): 555-560
33 Neiger R, Ramsey I, O’Connor J et al. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150(26): 799-804
34 Pallauf A, Beuschlein F. Mikro- und makronoduläre ACTH-unabhängige Nebennieren-Hyperplasie. Journal für Klinische Endokrinologie und Stoffwechsel 2010; 3(3): 34-39
35 Pollard RE, Reilly CM, Uerling MR et al. Cross-sectional imaging characteristics of pituitary adenomas, invasive adenomas and adenocarcinomas in dogs: 33 cases (1988–2006). J Vet Intern Med 2010; 24: 160-165
36 Ramsey IK, Richardson J, Lenard Z et al. Persistent isolated hypercorticolism following brief treatment with trilostane. Aust Vet J 2008; 86(12): 491-495
37 Reusch C, Glaus T, Wess G et al. Klinische, labordiagnostische und spezielle endokrinologische Untersuchungen bei Hunden mit hypophysärem Cushing-Syndrom: ein Vergleich zwischen Hunden mit Makro- und solchen mit Mikrotumoren. Kleintierpraxis 2001; 46: 261-270
38 Reusch CE. Hyperadrenocorticism. In: Ettinger SJ, Feldman EC (Hrsg ): Textbook of Veterinary Internal Medicine. 6. Aufl. St. Louis Missouri Elsevier; 2005, 1592-1612
39 Reusch CE, Sieber-Ruckstuhl N, Wenger M et al. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane. Vet Rec 2007; 160(7): 219-224
40 Reusch CE. Erkrankungen endokriner Drüsen. In: Suter PF, Kohn B, Schwarz G, (Hrsg ) Praktikum der Hundeklinik. Stuttgart: Enke Verlag; 2012: 888-922
41 Reusch CE. Tumoren der Hypophyse, Tumoren der Nebenniere, Tumoren des endokrinen Pankreas. In: Kessler M, (Hrsg) Kleintieronkologie. Stuttgart: Enke; (im Druck)
42 Ristic JM, Ramsey IK, Heath EM. The use of 17-hydroxyprogesterone in the diagnosis of canine hyperadrenocorticism. J Vet Intern Med 2002; 16: 433-439
43 Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002; 63(4): 506-512
44 Scott-Moncrieff JC, Koshko MA, Brown JA et al. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol 2003; 32(4): 180-187
45 Sieber-Ruckstuhl NS, Boretti FS, Wenger M et al. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Domest Anim Endocrinol 2006; 31(1): 63-75
46 Sieber-Ruckstuhl NS, Boretti FS, Wenger M et al. Evaluation of cortisol precursors for the diagnosis of pituitary-dependent hypercortisolism in dogs. Vet Rec 2008a 162: 673-678
47 Sieber-Ruckstuhl NS, Boretti FS, Wenger M et al. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Vet Rec 2008b 163(16): 477-481
48 Van der Vlugt-Meijer RH, Meij BP, den Ingh T van et al. Dynamic computed tomography of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2003; 17: 773-780
49 Vaughan MA, Feldman EC, Hoar BR et al. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2008; 232(9): 1321-1328
50 Wenger M, Sieber-Ruckstuhl NS, Müller C et al. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 2004; 65(9): 1245-1250
51 Witt AL, Neiger R. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy. Vet Rec 2004; 154(13): 399-400
52 Zeugswetter FK, Pagitz M, Hittmair K et al. Klinische Anwendung einer chemiluminometrischen ACTH-Bestimmung beim caninen Hyperadrenocortizismus. Schweiz Arch Tierheilk 2011; 153(3): 111-116
53 Zur G, White SD. Hyperadrenocorticism in 10 dogs with skin lesions as the only presenting clinical signs. J Am Anim Hosp Assoc 2011; 47(6) 419–427